Phase 2b study to evaluate the rate of onset of action of RDX227675 along with safety and efficacy in patients with chronic kidney disease (CKD) with or without heart failure (HF)

Trial Profile

Phase 2b study to evaluate the rate of onset of action of RDX227675 along with safety and efficacy in patients with chronic kidney disease (CKD) with or without heart failure (HF)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jan 2017

At a glance

  • Drugs RDX 7675 (Primary)
  • Indications Hyperkalaemia; Kidney disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jan 2017 Status changed from planning to recruiting, as per an Ardelyx media release.
    • 28 Jun 2016 New trial record
    • 22 Jun 2016 According to Ardelyx media release, this study is in accordance with FDA's request to evaluate onset of action of RDX227675.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top